Yondelis Side Effects

Generic name: trabectedin

Medically reviewed by Drugs.com. Last updated on Sep 10, 2023.

Note: This document provides detailed information about Yondelis Side Effects associated with trabectedin. Some dosage forms listed on this page may not apply specifically to the brand name Yondelis.

Applies to trabectedin: intravenous powder for solution.

Serious side effects of Yondelis

Along with its needed effects, trabectedin (the active ingredient contained in Yondelis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking trabectedin:

More common

• chest discomfort or pain
• difficulty breathing
• dizziness
• faintness
• fast irregular or pounding heartbeat
• swelling of the feet or lower legs
• unusual tiredness or weakness

Less common

• dark-colored urine
• fever
• muscle cramps or spasms
• muscle pain or stiffness

Rare

• abdominal or stomach pain or tenderness
• clay colored stools
• decreased appetite
• headache
• itching or skin rash
• loss of appetite
• nausea and vomiting
• swelling of the feet or lower legs
• yellow eyes or skin

Incidence not known

• black, tarry stools
• chills
• cough
• difficulty with swallowing
• hives
• lower back or side pain
• painful or difficult urination
• pale skin
• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
• sore throat
• tightness in the chest
• ulcers, sores, or white spots in the mouth
• unusual bleeding or bruising

Other side effects of Yondelis

Some side effects of trabectedin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• diarrhea
• difficulty having a bowel movement (stool)
• decreased appetite
• headache
• trouble sleeping

Incidence not known

• pain at the injection site

For healthcare professionals

Applies to trabectedin: intravenous powder for injection.

Hepatic

• Very common (10% or more): Increased ALT (up to 96.1%), increased AST (up to 89.5%), increased alkaline phosphatase (up to 70%), hyperbilirubinemia (up to 25.2%), increased gamma-glutamyltransferase (% unavailable)
• Common (1% to 10%): Drug-induced liver injury
• Uncommon (0.1% to 1%): Hepatotoxicity
• Frequency not reported: Hepatic failure, increased conjugated bilirubin^[Ref]

Hematologic

• Very common (10% or more): Anemia (up to 96%), neutropenia (up to 91.6%), leukopenia (up to 94.9%), thrombocytopenia (up to 63.7%)
• Common (1% to 10%): Febrile neutropenia, neutropenic sepsis, pancytopenia, bone marrow failure, granulocytopenia
• Uncommon (0.1% to 1%): Neutropenic infection^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (up to 75%), vomiting (up to 51.7%), constipation (up to 37%), diarrhea (up to 35%), stomatitis (up to 19.2%),
• Common (1% to 10%): Abdominal pain, dyspepsia, upper abdominal pain^[Ref]

Other

• Very common (10% or more): Fatigue/asthenia/malaise (up to 69%), peripheral edema (up to 28%), mucosal inflammation (up to 11.4%), pyrexia (up to 10.2%)
• Common (1% to 10%): Infection, edema, injection site reaction
• Uncommon (0.1% to 1%): Septic shock
• Frequency not reported: Multi-organ failure, catheter site reactions
• Postmarketing reports: Extravasation/tissue necrosis^[Ref]

Metabolic

• Very common (10% or more): Hypoalbuminemia (up to 63%), decreased appetite (up to 37%), anorexia (up to 28.8%)
• Common (1% to 10%): Dehydration, hypokalemia, decreased weight^[Ref]

Renal

• Very common (10% or more): Increased creatinine (up to 46%)
• Common (1% to 10%): Renal failure^[Ref]

Musculoskeletal

• Very common (10% or more): Elevated creatine phosphokinase (up to 33%), arthralgia (up to 15%), myalgia (up to 12%)
• Common (1% to 10%): Back pain
• Uncommon (0.1% to 1%): Rhabdomyolysis
• Frequency not reported: Musculoskeletal pain^[Ref]

Respiratory

• Very common (10% or more): Dyspnea (up to 25%)
• Common (1% to 10%): Cough, pulmonary embolism
• Uncommon (0.1% to 1%): Pulmonary edema^[Ref]

Nervous system

• Very common (10% or more): Headache (up to 25%)
• Common (1% to 10%): Peripheral neuropathy, dysgeusia, dizziness, paresthesia
• Uncommon (0.1% to 1%): Syncope
• Frequency not reported: Hypoesthesia^[Ref]

Dermatologic

• Very common (10% or more): Palmar-plantar erythrodysesthesia (up to 24%), alopecia (up to 12%)
• Common (1% to 10%): Rash, skin hyperpigmentation^[Ref]

Psychiatric

• Very common (10% or more): Insomnia (up to 15%)^[Ref]

Cardiovascular

• Common (1% to 10%): Cardiomyopathy, decreased ejection fraction, hypotension, flushing
• Uncommon (0.1% to 1%): Left ventricular dysfunction^[Ref]

Hypersensitivity

• Common (1% to 10%): Hypersensitivity reactions^[Ref]

Further information

Yondelis side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer